Viropro Enters Contractual Partnership With National Research Council-Biotechnology Research Institute

Viropro Inc. (OTC BB:VPRO.OB - News) (``Viropro’’) is pleased to announce that an important contractual partnership has been signed with the National Research Council- Biotechnology Research Institute (NRC-BRI) for the development of one of the company’s main products, a targeted high volume sales Monoclonal Antibody. NRC-BRI has granted Viropro an exclusive worldwide license for cutting edge intellectual property designed to increase the production of specific biopharmaceutical products in manufacturing processes.

The company intends to out-license this product to various biopharmaceutical manufacturing partners. Discussions to this effect are ongoing with a first contract expected to be signed by the end of 2007. Significant revenues are expected between 2008 and 2010 from out-licensing fees and royalties.

``This partnership represents the integration of selected NRC-BRI Intellectual Property and process development expertise to Viropro’s product development. It will minimize the company’s capital expenditure requirements and allow both scientific groups to team-up to advance our core business objectives,’’ said Jean-Marie Dupuy, Viropro’s President and CEO.

Dr. Michel Desrochers of NRC-BRI stated that ``It is with great pleasure that I see one of NRC-BRI’s technology platforms being used to support one of our promising biotech companies.’’